Series C · Biotech
Epicrispr Biotechnologies: Series C
Develops programmable epigenetic medicines to treat genetic diseases like FSHD
Funding history
Series C · This round$90M
Loading rounds…
Develops programmable epigenetic medicines to treat genetic diseases like FSHD